The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2011
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Jun 2011 New trial record